Repository logo
 

Diagnostic route is associated with care satisfaction independently of tumour stage: Evidence from linked English Cancer Patient Experience Survey and cancer registration data.

Published version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Pham, Tra My 
Gomez-Cano, Mayam 
Salika, Theodosia 
Jardel, Demian 
Abel, Gary A 

Abstract

BACKGROUND: Whether diagnostic route (e.g. emergency presentation) is associated with cancer care experience independently of tumour stage is unknown. METHODS: We analysed data on 18 590 patients with breast, prostate, colon, lung, and rectal cancers who responded to the 2014 English Cancer Patient Experience Survey, linked to cancer registration data on diagnostic route and tumour stage at diagnosis. We estimated odds ratios (OR) of reporting a negative experience of overall cancer care by tumour stage and diagnostic route (crude and adjusted for patient characteristic and cancer site variables) and examined their interactions with cancer site. RESULTS: After adjustment, the likelihood of reporting a negative experience was highest for emergency presenters and lowest for screening-detected patients with breast, colon, and rectal cancers (OR versus two-week-wait 1.51, 95% confidence interval [CI] 1.24-1.83; 0.88, 95% CI 0.75-1.03, respectively). Patients with the most advanced stage were more likely to report a negative experience (OR stage IV versus I 1.37, 95% CI 1.15-1.62) with little confounding between stage and route, and no evidence for cancer-stage or cancer-route interactions. CONCLUSIONS: Though the extent of disease is strongly associated with ratings of overall cancer care, diagnostic route (particularly emergency presentation or screening detection) exerts important independent effects.

Description

Keywords

Cancer, Diagnosis, Disparities, Patient, Stage, Survey

Journal Title

Cancer Epidemiology

Conference Name

Journal ISSN

1877-7821
1877-783X

Volume Title

61

Publisher

Elsevier
Sponsorship
This work is supported by Macmillan Cancer Support grant 5995414 for which GAA and GL are joint principal investigators. GL is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship Award (C18081/A18180).